JPWO2023178099A5 - - Google Patents

Info

Publication number
JPWO2023178099A5
JPWO2023178099A5 JP2024555045A JP2024555045A JPWO2023178099A5 JP WO2023178099 A5 JPWO2023178099 A5 JP WO2023178099A5 JP 2024555045 A JP2024555045 A JP 2024555045A JP 2024555045 A JP2024555045 A JP 2024555045A JP WO2023178099 A5 JPWO2023178099 A5 JP WO2023178099A5
Authority
JP
Japan
Prior art keywords
caution
membered
alkyl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509697A5 (https=
JP2025509697A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064332 external-priority patent/WO2023178099A1/en
Publication of JP2025509697A publication Critical patent/JP2025509697A/ja
Publication of JP2025509697A5 publication Critical patent/JP2025509697A5/ja
Publication of JPWO2023178099A5 publication Critical patent/JPWO2023178099A5/ja
Pending legal-status Critical Current

Links

JP2024555045A 2022-03-15 2023-03-14 Nlrp3モジュレーター Pending JP2025509697A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263320157P 2022-03-15 2022-03-15
US63/320,157 2022-03-15
US202263356415P 2022-06-28 2022-06-28
US63/356,415 2022-06-28
PCT/US2023/064332 WO2023178099A1 (en) 2022-03-15 2023-03-14 Nlrp3 modulators

Publications (3)

Publication Number Publication Date
JP2025509697A JP2025509697A (ja) 2025-04-11
JP2025509697A5 JP2025509697A5 (https=) 2026-03-19
JPWO2023178099A5 true JPWO2023178099A5 (https=) 2026-03-19

Family

ID=88024503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555045A Pending JP2025509697A (ja) 2022-03-15 2023-03-14 Nlrp3モジュレーター

Country Status (14)

Country Link
US (1) US20230295113A1 (https=)
EP (1) EP4493556A4 (https=)
JP (1) JP2025509697A (https=)
KR (1) KR20250004658A (https=)
CN (1) CN119301116A (https=)
AU (1) AU2023234527A1 (https=)
CA (1) CA3255244A1 (https=)
CL (1) CL2024002767A1 (https=)
CO (1) CO2024013744A2 (https=)
GE (1) GEAP202516611A (https=)
IL (1) IL315592A (https=)
MX (1) MX2024011254A (https=)
TW (1) TW202345834A (https=)
WO (1) WO2023178099A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024157953A1 (ja) * 2023-01-24 2024-08-02 第一三共株式会社 置換ベンゼン化合物
WO2024251073A1 (zh) * 2023-06-03 2024-12-12 成都赜灵生物医药科技有限公司 并哒嗪类化合物及其用途
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025255533A1 (en) * 2024-06-07 2025-12-11 Zomagen Biosciences Ltd Combination therapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
KR20230035049A (ko) * 2020-07-02 2023-03-10 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
CA3251149A1 (en) * 2022-05-13 2023-11-16 Neumora Therapeutics, Inc. NLRP3 INFLAMMASOME MODULATORS, ASSOCIATED PRODUCTS AND PROCESSES

Similar Documents

Publication Publication Date Title
JPWO2023278438A5 (https=)
JP2020528889A5 (https=)
JP2019519598A5 (https=)
JP2020529405A5 (https=)
JP2020537657A5 (https=)
JP2011513367A5 (https=)
JP2009524691A5 (https=)
JPWO2022040600A5 (https=)
JPWO2023178099A5 (https=)
JP2021523200A5 (https=)
JPWO2019232419A5 (https=)
JPWO2020103815A5 (https=)
JP2017531016A5 (https=)
KR20100122489A (ko) 아제티딘-유도 화합물, 그의 제조 방법 및 그의 치료학적 용도
JP2021528405A5 (https=)
JP2019537624A5 (https=)
JP2019524752A5 (https=)
JP2018537480A5 (https=)
JPWO2021009566A5 (https=)
JPWO2021071821A5 (https=)
JPWO2021009567A5 (https=)
KR20100098563A (ko) 아제티딘 유도체, 그의 제법 및 치료에서의 그의 적용
JPWO2020163778A5 (https=)
JPWO2020180624A5 (https=)
JPWO2023118507A5 (https=)